What if competitors could collaborate and innovate together while ensuring data security? FLuID (published in Nature Machine Intelligence) makes it possible. This federated learning approach allows companies to combine expertise to build better models for drug discovery and beyond. Discover how this could be a blueprint for responsible innovation by reading more here https://lnkd.in/eZ-J4WMf
About us
UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2024 Key Financials: € 6.15 billion global revenue Specialties: Neurology, Immunology
- Website
-
http://www.ucb.com
External link for UCB
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Brussels
- Type
- Privately Held
- Founded
- 1928
- Specialties
- Neurology, Immunology, and Healthcare Innovation Beyond Medicine
Locations
Employees at UCB
Updates
-
UCB reposted this
We recently published our 2024 Full Year results – and with them, our UCB Integrated Annual Report. 📖 It is a comprehensive document that deep dives into our financial, social and environmental performance. Fully aligned to EU #CSRD reporting requirements, it provides transparent information on how we are creating value for people living with severe neurological and immunological diseases, for our colleagues at UCB, our shareholders, the communities where we operate while decreasing our environmental footprint. For us, driving sustainable performance i.e. financial, social and environmental performance is not only a way to be an active economic agent in society but it is also an imperative for businesses that operate with future generations in mind. 🤝 We're all in this together – colleagues, partners, scientific and patient communities - working towards a healthier future for people with severe diseases and society overall. Explore our Report to understand how in details 👉 https://reports.ucb.com ✨ Many thanks to all #TeamUCB colleagues across the globe who contributed to the impact we created in 2024! #Innovation #Sustainability #SocialImpact #Fitforfuture #reporting Luc Uylenbroeck Sophie Housiaux Benoit Marchioni Lissiah Taylor Hundley JD Anisa Dhalla Alexandra Moutet M.D. Anne-laure Demarcy Nicole Reis Camila Neves de Santana Daniela Urquiza Travi Chiara Montecucco Laurène Viviani Sahar Yazdian Caroline Vancoillie Xavier Michel Gwendoline Ornigg Antje Witte
-
Confidential data silos are one of the biggest obstacles to collaboration in science and innovation. Enter FLuID, a novel approach that allows pharmaceutical companies to securely share critical insights without exposing sensitive data. Now published in Nature Machine Intelligence, this research showcases a privacy-first framework for groundbreaking collaboration. Explore this visionary work and its potential to transform not only drug discovery but countless other industries. You can read more here https://lnkd.in/eZ-J4WMf
-
-
Revolutionizing collaboration without compromising privacy - that’s the promise of FLuID (Federated Learning Using Information Distillation). Recently published in Nature Machine Intelligence, this new methodology aims to transform how pharmaceutical companies share insights to build better predictive models while keeping their data private. Curious about how FLuID works and its application in drug discovery? Read more here https://lnkd.in/eZ-J4WMf
-
We are proud to share the incredible recognition received by The Unbearable Home campaign at the recent PM Society Awards, where it earned five awards, including the prestigious Best in Show! 🏆 🏅 Gold for Best Disease Awareness Campaign for HCPs 🏅 Gold for Best Use of Insights 🏅 Gold for Best Design Craft 🥈 Silver for Meetings and Exhibitions ✨ Best in Show Award Rooted in the lived experiences of real patients, this campaign was designed to make HS (hidradenitis suppurativa) more visible to healthcare professionals. By combining patient insights with bold, creative storytelling, it shined a light on the physical and emotional challenges faced by those impacted by HS. Judges praised its ability to create a genuine emotional connection with its audience, motivating dermatologists to take action and strive for better patient outcomes. The Unbearable Home reflects our broader commitment to improving understanding, care, and outcomes in HS. This recognition strengthens our resolve to continue working alongside the HS community to drive meaningful progress and amplify the voices of those living with this condition. If you’d like to explore more about The PM Society Awards, find out more here: https://lnkd.in/eyGPPZSE #PharmaMarketing #HSawareness #DrivingProgress #AwardWinningCampaign Chiara Danelli
-
-
With Muscular Dystrophy Association well underway in Dallas, read more about our work in #TK2d and how we are driven by a commitment to people living with severe diseases. https://lnkd.in/eMMWkwdB #MDAConference #Research
-
This #MDAconference learn more about the profound physical challenges and severe psychological strain that come with living with #TK2d, and the heavy emotional and physical burden experienced by caregivers.
-
On #WORDDAY2025, we join the global effort to raise awareness about rheumatic diseases in children and young people. Too often, conditions such as rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis are misunderstood or overlooked, delaying the critical care young patients need. At UCB, we are dedicated to advancing the standard of care in rheumatic diseases. We believe that early diagnosis and timely referrals to specialists can transform lives—not just for children and adolescents affected, but for their families, too. To make this a reality, we must work together to increase understanding. Parents, doctors, teachers, and the public all play a role in recognizing symptoms and ensuring no child or young person faces this challenge alone. Together, we can build a future of hope and improved outcomes. Let’s spread the word and make a difference. #WORDDAY2025 #RheumaticDiseases #ElevatingCare Learn more: https://lnkd.in/eGvEgndy
-
-
Attending #MDAconference in Dallas? Don’t miss the #UCB forum with renowned expert, Dr. Michio Hirano, who will explore key differences between genetic testing & muscle biopsy in diagnosing mitochondrial myopathies. Join us on March 17 with lunch at 12pm. #TK2d
-
-
When talent meets purpose, extraordinary things happen. We're cultivating a workplace where every voice matters and every perspective is valued. Together, we're building careers with meaning while making a lasting difference to people living with severe diseases. Discover a future where professional growth and patient impact go hand in hand. #MakeYourMarkForPatients #TeamUCB #PharmaJobs Learn more at UCB Careers https://lnkd.in/dHkyid5y
-